NCT05707481Completed
Impact of Clinical Pharmacist-Led Intervention on Management of Diabetic Hypertensive Patients in Eastern Nepal
Impact of Clinical Pharmacist Led Intervention on Management of Diabetic Hypertensive Patients.
Source: ClinicalTrials.gov · Last updated 12 Feb 2025
Brief summary (registry, in English)
Diabetic-Hypertensives are at a higher risk of premature microvascular and macrovascular complications than diabetes alone. Proper lifestyle management, diet, disease monitoring, and medication adherence is essential in achieving desired therapeutic outcomes, preventing complications and improving those patients' Health-Related Quality of Life (HRQoL). Pharmacists are the most accessible healthcare professionals to the public and have a crucial role in optimizing treatment outcomes in patients with chronic diseases such as diabetes and hypertension. Experimental trials' demonstrating the potential roles of pharmaceutical services is scarce in the literature, particularly in developing countries of south Asia. Therefore, the investigators plan to conduct a prospective-interventional trial to determine the potential impacts of pharmacist-supervised educational intervention on the management of "Type II diabetic with comorbid hypertension" patients. Patient data will be collected using patient's clinical profile forms, General Medication adherence Scale (GMAS), Patients Satisfaction towards pharmaceutical services (PSPSQ), Health Related-KAP questionnaires. Data will be verified, stored, entered into databases, and analyzed according to the data management plan. The findings will be compared in terms of clinical and nonclinical outcome measures between the control and test groups to ascertain the conclusion.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 92 (actual)
- First submitted
- 6 Jan 2023
- Start date
- 22 Aug 2023
- Primary completion date
- 2 Jul 2024
- Lead sponsor
- Chettinad Academy of Research and Education (Deemed to be University)
- Diseases
- High blood pressure, Type 2 diabetes
- NCT number
- NCT05707481
What you commit to
- Study type: Interventional
- Participants enrolled: 92
- From 22 Aug 2023 to the primary completion date, 2 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with Type I diabetes mellitus, Diabetic insipidus, Gestational diabetes or other forms of diabetes.
- Presence of other chronic disease co-morbidity other than hypertension and diabetes complications.
- Patients have tuberculosis, Corona virus, and other highly communicable diseases.
Other
- Mentally incompetent patients, Pregnant, critically ill patients (requiring hospital admission).
- Those patients not willing to performing routine follow-up visit.
Who the study is looking for
- Male and female patients aged 40 to 68 years.
- Clinically diagnosed with type II diabetes mellitus with hypertension as co-morbidity.
- Minimum one year of the medical history of diabetic and hypertension.
- Minimum 6 months on antidiabetic as well as antihypertensive medication therapy.
- Patients willing to participate in the study and those providing written informed consent for participation.
Age in the registry: 40 years to 68 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Purbanchal University Hospital Coordinator of this site? Confirm its status | Gothgaun,Sundar Haraicha Municipality, Morang | Nepal | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.